support_agent

Your contact persons

CHEPLAPHARM Arzneimittel GmbH

View:
format_list_bulleted grid_view

08/27/2025

CHEPLAPHARM with stable business in the first half of 2025
Press releases
Read more chevron_right

08/07/2025

Tender Offer Final Results Announcement
Press releases
Read more chevron_right

07/23/2025

Tender Offer Early Results Announcement
Press releases
Read more chevron_right

07/16/2025

CHEPLAPHARM expands collaboration with Boryung (South Korea) in manufacture of Zyprexa® tablets
Press releases
Read more chevron_right

07/09/2025

Tender Offer Launch Release
Press releases
Read more chevron_right

07/02/2025

Satisfaction Notice to Conditional Redemption
Press releases
Read more chevron_right

06/26/2025

High Demand and Attractive Pricing: CHEPLAPHARM's New 7.125% Bond Multiple Times Oversubscribed
Press releases
Read more chevron_right

06/19/2025

Notice on Conditional Full Redemption
Press releases
Read more chevron_right

06/18/2025

CHEPLAPHARM Arzneimittel GmbH Announces Pricing of €750,000,000 7.125% Senior Secured Notes due 2031
Press releases
Read more chevron_right

06/16/2025

CHEPLAPHARM Arzneimittel GmbH Announces Offering of Senior Secured Notes due 2031
Press releases
Read more chevron_right
Back to top expand_less